<clinical_study>
  <!-- This xml conforms to an XML Schema at:
    https://clinicaltrials.gov/ct2/html/images/info/public.xsd -->
  <required_header>
    <download_date>ClinicalTrials.gov processed this data on May 29, 2018</download_date>
    <link_text>Link to the current ClinicalTrials.gov record.</link_text>
    <url>https://clinicaltrials.gov/show/NCT01044212</url>
  </required_header>
  <id_info>
    <org_study_id>29359</org_study_id>
    <nct_id>NCT01044212</nct_id>
  </id_info>
  <brief_title>Bowel Function After Minimally Invasive Urogynecologic Surgery</brief_title>
  <official_title>Bowel Function After Minimally Invasive Urogynecologic Surgery: A Prospective Randomized Controlled Trial</official_title>
  <sponsors>
    <lead_sponsor>
      <agency>University of Rochester</agency>
      <agency_class>Other</agency_class>
    </lead_sponsor>
  </sponsors>
  <source>University of Rochester</source>
  <oversight_info>
    <has_dmc>No</has_dmc>
  </oversight_info>
  <brief_summary>
    <textblock>
      The purpose of this study is to assess the effect of a standardized postoperative bowel
      regimen of over-the-counter medications in subjects undergoing minimally invasive
      urogynecologic surgery.
    </textblock>
  </brief_summary>
  <detailed_description>
    <textblock>
      See above
    </textblock>
  </detailed_description>
  <overall_status>Completed</overall_status>
  <start_date>November 2009</start_date>
  <completion_date type="Actual">February 2011</completion_date>
  <primary_completion_date type="Actual">February 2011</primary_completion_date>
  <phase>N/A</phase>
  <study_type>Interventional</study_type>
  <has_expanded_access>No</has_expanded_access>
  <study_design_info>
    <allocation>Randomized</allocation>
    <intervention_model>Parallel Assignment</intervention_model>
    <primary_purpose>Prevention</primary_purpose>
    <masking>None (Open Label)</masking>
  </study_design_info>
  <primary_outcome>
    <measure>Time to First Post-op Bowel Movement</measure>
    <time_frame>Within 1 week of surgery</time_frame>
    <description>The time to first post-operative bowel movement was measured in hours after surgery.</description>
  </primary_outcome>
  <secondary_outcome>
    <measure>Pain Level Associated With First Postoperative Bowel Movement</measure>
    <time_frame>Within 1 week of surgery</time_frame>
    <description>The pain level experienced with the first post-operative bowel movement was recorded and measured on visual analog score with range 0 to 10 in units on scale. 0 being no pain at all. 10 being worst pain.</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Consistency of First Postoperative Bowel Movement</measure>
    <time_frame>Within 1 week of surgery</time_frame>
    <description>The consistency of the first post-operative bowel movement was rated using the Bristol Stool Scale. This is a validated scale that is widely used. It is given to patients as a chart. The chart can be seen here: http://en.wikipedia.org/wiki/Bristol_stool_scale.
The seven types of stool are:
Type 1: Separate hard lumps, like nuts (hard to pass) Type 2: Sausage-shaped, but lumpy Type 3: Like a sausage but with cracks on its surface Type 4: Like a sausage or snake, smooth and soft Type 5: Soft blobs with clear cut edges (passed easily) Type 6: Fluffy pieces with ragged edges, a mushy stool Type 7: Watery, no solid pieces. Entirely liquid</description>
  </secondary_outcome>
  <number_of_arms>2</number_of_arms>
  <enrollment type="Actual">72</enrollment>
  <condition>Functional Disorder of Intestine</condition>
  <arm_group>
    <arm_group_label>Docusate</arm_group_label>
    <arm_group_type>Active Comparator</arm_group_type>
    <description>Docusate is the standard of care regimen</description>
  </arm_group>
  <arm_group>
    <arm_group_label>Bowel medications</arm_group_label>
    <arm_group_type>Experimental</arm_group_type>
    <description>Docusate, Miralax, Metamucil wafers, Bisacodyl suppository</description>
  </arm_group>
  <intervention>
    <intervention_type>Drug</intervention_type>
    <intervention_name>Docusate</intervention_name>
    <description>Docusate 100mg BID</description>
    <arm_group_label>Docusate</arm_group_label>
    <other_name>Colace</other_name>
  </intervention>
  <intervention>
    <intervention_type>Drug</intervention_type>
    <intervention_name>Bowel medications</intervention_name>
    <description>Docusate 100mg BID Metamucil fiber wafers - 2 wafers daily Miralax 1 packet daily Bisacodyl 1 suppository BID</description>
    <arm_group_label>Bowel medications</arm_group_label>
    <other_name>Colace</other_name>
    <other_name>Psyllium</other_name>
    <other_name>Polyethylene glycol</other_name>
    <other_name>Dulcolax</other_name>
  </intervention>
  <eligibility>
    <criteria>
      <textblock>
        Inclusion Criteria:

          -  Planning to be admitted to the hospital to undergo minimally-invasive urogynecologic
             surgery at Strong Memorial Hospital.

        Procedures may include:

          -  robot-assisted laparoscopic sacrocolpopexy

          -  sacrospinous ligament suspension

          -  uterosacral ligament suspension/paravaginal defect repair

          -  colpocleisis

          -  cystocele repair

        Additional procedures may include:

          -  hysterectomy

          -  adnexectomy

          -  culdoplasty

          -  minimally invasive sling procedure (TVT or TOT)

          -  periurethral collagen injections

          -  enterocele repair

        Exclusion Criteria:

          -  Planning to undergo laparotomy.

          -  Undergoing rectocele or perineocele repair as part of surgery.

          -  Taking Miralax, laxatives, enemas, or suppositories daily, at the time of enrollment.

          -  Presence of a colostomy.

          -  Chronic kidney disease

          -  Insulin-dependent diabetes mellitus

          -  Known cardiac disease

          -  Gastric ulcers

          -  Difficulty swallowing or esophageal stricture

          -  Persistent nausea and vomiting

          -  Signs and symptoms consistent with bowel obstruction
      </textblock>
    </criteria>
    <gender>Female</gender>
    <minimum_age>18 Years</minimum_age>
    <maximum_age>89 Years</maximum_age>
    <healthy_volunteers>Accepts Healthy Volunteers</healthy_volunteers>
  </eligibility>
  <overall_official>
    <last_name>Gunhilde Buchsbaum, MD</last_name>
    <role>Principal Investigator</role>
    <affiliation>University of Rochester</affiliation>
  </overall_official>
  <location>
    <facility>
      <name>University of Rochester</name>
      <address>
        <city>Rochester</city>
        <state>New York</state>
        <zip>14642</zip>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location_countries>
    <country>United States</country>
  </location_countries>
  <verification_date>September 2015</verification_date>
  <!-- For several months we've had both old and new date name tags                             -->
  <!-- Now, the old date names have been dropped.                                               -->
  <!-- The new date name replacements are:                                                      -->
  <!--     OLD (gone)                                        NEW (in use)                       -->
  <!--   lastchanged_date                         becomes   last_update_submitted               -->
  <!--   firstreceived_date                       becomes   study_first_submitted               -->
  <!--   firstreceived_results_date               becomes   results_first_submitted             -->
  <!--   firstreceived_results_disposition_date   becomes   disposition_first_submitted         -->
  <study_first_submitted>January 5, 2010</study_first_submitted>
  <study_first_submitted_qc>January 6, 2010</study_first_submitted_qc>
  <study_first_posted type="Estimate">January 7, 2010</study_first_posted>
  <results_first_submitted>September 14, 2012</results_first_submitted>
  <results_first_submitted_qc>September 21, 2015</results_first_submitted_qc>
  <results_first_posted type="Estimate">October 21, 2015</results_first_posted>
  <last_update_submitted>September 21, 2015</last_update_submitted>
  <last_update_submitted_qc>September 21, 2015</last_update_submitted_qc>
  <last_update_posted type="Estimate">October 21, 2015</last_update_posted>
  <responsible_party>
    <responsible_party_type>Principal Investigator</responsible_party_type>
    <investigator_affiliation>University of Rochester</investigator_affiliation>
    <investigator_full_name>Gunhilde Buchsbaum</investigator_full_name>
    <investigator_title>Professor</investigator_title>
  </responsible_party>
  <keyword>Urogynecology</keyword>
  <condition_browse>
    <!-- CAUTION:  The following MeSH terms are assigned with an imperfect algorithm            -->
    <mesh_term>Intestinal Diseases</mesh_term>
    <mesh_term>Gastrointestinal Diseases</mesh_term>
  </condition_browse>
  <intervention_browse>
    <!-- CAUTION:  The following MeSH terms are assigned with an imperfect algorithm            -->
    <mesh_term>Bismuth subsalicylate</mesh_term>
  </intervention_browse>

  <clinical_results>

    <participant_flow>
      <recruitment_details>Candidates meeting criteria were offered participation at their preoperative visit.</recruitment_details>
      <group_list>
        <group group_id="P1">
          <title>Bowel Medications</title>
          <description>Docusate, Miralax, Metamucil wafers, Bisacodyl suppository
Bowel medications : Docusate 100mg BID Metamucil fiber wafers - 2 wafers daily Miralax 1 packet daily Bisacodyl 1 suppository BID</description>
        </group>
        <group group_id="P2">
          <title>Docusate Controls</title>
          <description>Docusate is the standard of care regimen
Docusate sodium : Docusate 100mg BID</description>
        </group>
      </group_list>
      <period_list>
        <period>
          <title>Overall Study</title>
          <milestone_list>
            <milestone>
              <title>STARTED</title>
              <participants_list>
                <participants group_id="P1" count="35"/>
                <participants group_id="P2" count="37"/>
              </participants_list>
            </milestone>
            <milestone>
              <title>COMPLETED</title>
              <participants_list>
                <participants group_id="P1" count="30"/>
                <participants group_id="P2" count="30"/>
              </participants_list>
            </milestone>
            <milestone>
              <title>NOT COMPLETED</title>
              <participants_list>
                <participants group_id="P1" count="5"/>
                <participants group_id="P2" count="7"/>
              </participants_list>
            </milestone>
          </milestone_list>
        </period>
      </period_list>
    </participant_flow>

    <baseline>
      <group_list>
        <group group_id="B1">
          <title>Bowel Medications</title>
          <description>Docusate, Miralax, Metamucil wafers, Bisacodyl suppository
Bowel medications : Docusate 100mg BID Metamucil fiber wafers - 2 wafers daily Miralax 1 packet daily Bisacodyl 1 suppository BID</description>
        </group>
        <group group_id="B2">
          <title>Docusate Controls</title>
          <description>Docusate is the standard of care regimen
Docusate sodium : Docusate 100mg BID</description>
        </group>
        <group group_id="B3">
          <title>Total</title>
          <description>Total of all reporting groups</description>
        </group>
      </group_list>
      <analyzed_list>
        <analyzed>
          <units>Participants</units>
          <scope>Overall</scope>
          <count_list>
            <count group_id="B1" value="35"/>
            <count group_id="B2" value="37"/>
            <count group_id="B3" value="72"/>
          </count_list>
        </analyzed>
      </analyzed_list>
      <measure_list>
        <measure>
          <title>Age</title>
          <units>participants</units>
          <param>Number</param>
          <class_list>
            <class>
              <title>&lt;=18 years</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="B1" value="0"/>
                    <measurement group_id="B2" value="0"/>
                    <measurement group_id="B3" value="0"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>Between 18 and 65 years</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="B1" value="19"/>
                    <measurement group_id="B2" value="29"/>
                    <measurement group_id="B3" value="48"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>&gt;=65 years</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="B1" value="16"/>
                    <measurement group_id="B2" value="8"/>
                    <measurement group_id="B3" value="24"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
        <measure>
          <title>Age</title>
          <units>years</units>
          <param>Mean</param>
          <dispersion>Standard Deviation</dispersion>
          <class_list>
            <class>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="B1" value="58" spread="10"/>
                    <measurement group_id="B2" value="63" spread="9"/>
                    <measurement group_id="B3" value="61" spread="9.5"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
        <measure>
          <title>Gender</title>
          <units>participants</units>
          <param>Number</param>
          <class_list>
            <class>
              <title>Female</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="B1" value="35"/>
                    <measurement group_id="B2" value="37"/>
                    <measurement group_id="B3" value="72"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>Male</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="B1" value="0"/>
                    <measurement group_id="B2" value="0"/>
                    <measurement group_id="B3" value="0"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
        <measure>
          <title>Region of Enrollment</title>
          <units>participants</units>
          <param>Number</param>
          <class_list>
            <class>
              <title>United States</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="B1" value="35"/>
                    <measurement group_id="B2" value="37"/>
                    <measurement group_id="B3" value="72"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
      </measure_list>
    </baseline>

    <outcome_list>
      <outcome>
        <type>Primary</type>
        <title>Time to First Post-op Bowel Movement</title>
        <description>The time to first post-operative bowel movement was measured in hours after surgery.</description>
        <time_frame>Within 1 week of surgery</time_frame>
        <population>Power analysis</population>
        <group_list>
          <group group_id="O1">
            <title>Bowel Medications</title>
            <description>Docusate, Miralax, Metamucil wafers, Bisacodyl suppository
Bowel medications : Docusate 100mg BID Metamucil fiber wafers - 2 wafers daily Miralax 1 packet daily Bisacodyl 1 suppository BID</description>
          </group>
          <group group_id="O2">
            <title>Docusate Controls</title>
            <description>Docusate is the standard of care regimen
Docusate sodium : Docusate 100mg BID</description>
          </group>
        </group_list>
        <measure>
          <title>Time to First Post-op Bowel Movement</title>
          <description>The time to first post-operative bowel movement was measured in hours after surgery.</description>
          <population>Power analysis</population>
          <units>hours</units>
          <param>Mean</param>
          <dispersion>Standard Deviation</dispersion>
          <analyzed_list>
            <analyzed>
              <units>Participants</units>
              <scope>Measure</scope>
              <count_list>
                <count group_id="O1" value="30"/>
                <count group_id="O2" value="30"/>
              </count_list>
            </analyzed>
          </analyzed_list>
          <class_list>
            <class>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="64" spread="21"/>
                    <measurement group_id="O2" value="77" spread="24"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
      </outcome>
      <outcome>
        <type>Secondary</type>
        <title>Pain Level Associated With First Postoperative Bowel Movement</title>
        <description>The pain level experienced with the first post-operative bowel movement was recorded and measured on visual analog score with range 0 to 10 in units on scale. 0 being no pain at all. 10 being worst pain.</description>
        <time_frame>Within 1 week of surgery</time_frame>
        <group_list>
          <group group_id="O1">
            <title>Bowel Medications</title>
            <description>Docusate, Miralax, Metamucil wafers, Bisacodyl suppository
Bowel medications : Docusate 100mg BID Metamucil fiber wafers - 2 wafers daily Miralax 1 packet daily Bisacodyl 1 suppository BID</description>
          </group>
          <group group_id="O2">
            <title>Docusate Controls</title>
            <description>Docusate is the standard of care regimen
Docusate sodium : Docusate 100mg BID</description>
          </group>
        </group_list>
        <measure>
          <title>Pain Level Associated With First Postoperative Bowel Movement</title>
          <description>The pain level experienced with the first post-operative bowel movement was recorded and measured on visual analog score with range 0 to 10 in units on scale. 0 being no pain at all. 10 being worst pain.</description>
          <units>VAS pain score</units>
          <param>Mean</param>
          <dispersion>Standard Deviation</dispersion>
          <analyzed_list>
            <analyzed>
              <units>Participants</units>
              <scope>Measure</scope>
              <count_list>
                <count group_id="O1" value="35"/>
                <count group_id="O2" value="37"/>
              </count_list>
            </analyzed>
          </analyzed_list>
          <class_list>
            <class>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="3.6" spread="3.2"/>
                    <measurement group_id="O2" value="3.7" spread="2.8"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
      </outcome>
      <outcome>
        <type>Secondary</type>
        <title>Consistency of First Postoperative Bowel Movement</title>
        <description>The consistency of the first post-operative bowel movement was rated using the Bristol Stool Scale. This is a validated scale that is widely used. It is given to patients as a chart. The chart can be seen here: http://en.wikipedia.org/wiki/Bristol_stool_scale.
The seven types of stool are:
Type 1: Separate hard lumps, like nuts (hard to pass) Type 2: Sausage-shaped, but lumpy Type 3: Like a sausage but with cracks on its surface Type 4: Like a sausage or snake, smooth and soft Type 5: Soft blobs with clear cut edges (passed easily) Type 6: Fluffy pieces with ragged edges, a mushy stool Type 7: Watery, no solid pieces. Entirely liquid</description>
        <time_frame>Within 1 week of surgery</time_frame>
        <group_list>
          <group group_id="O1">
            <title>Bowel Medications</title>
            <description>Docusate, Miralax, Metamucil wafers, Bisacodyl suppository
Bowel medications : Docusate 100mg BID Metamucil fiber wafers - 2 wafers daily Miralax 1 packet daily Bisacodyl 1 suppository BID</description>
          </group>
          <group group_id="O2">
            <title>Docusate Controls</title>
            <description>Docusate is the standard of care regimen
Docusate sodium : Docusate 100mg BID</description>
          </group>
        </group_list>
        <measure>
          <title>Consistency of First Postoperative Bowel Movement</title>
          <description>The consistency of the first post-operative bowel movement was rated using the Bristol Stool Scale. This is a validated scale that is widely used. It is given to patients as a chart. The chart can be seen here: http://en.wikipedia.org/wiki/Bristol_stool_scale.
The seven types of stool are:
Type 1: Separate hard lumps, like nuts (hard to pass) Type 2: Sausage-shaped, but lumpy Type 3: Like a sausage but with cracks on its surface Type 4: Like a sausage or snake, smooth and soft Type 5: Soft blobs with clear cut edges (passed easily) Type 6: Fluffy pieces with ragged edges, a mushy stool Type 7: Watery, no solid pieces. Entirely liquid</description>
          <units>Bristol Stool Scale</units>
          <param>Mean</param>
          <dispersion>Standard Deviation</dispersion>
          <analyzed_list>
            <analyzed>
              <units>Participants</units>
              <scope>Measure</scope>
              <count_list>
                <count group_id="O1" value="35"/>
                <count group_id="O2" value="37"/>
              </count_list>
            </analyzed>
          </analyzed_list>
          <class_list>
            <class>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="3.13" spread="1.22"/>
                    <measurement group_id="O2" value="3.40" spread="1.07"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
      </outcome>
    </outcome_list>

    <reported_events>
      <group_list>
        <group group_id="E1">
          <title>Bowel Medications</title>
          <description>Docusate, Miralax, Metamucil wafers, Bisacodyl suppository
Bowel medications : Docusate 100mg BID Metamucil fiber wafers - 2 wafers daily Miralax 1 packet daily Bisacodyl 1 suppository BID</description>
        </group>
        <group group_id="E2">
          <title>Docusate Controls</title>
          <description>Docusate is the standard of care regimen
Docusate sodium : Docusate 100mg BID</description>
        </group>
      </group_list>
      <serious_events>
        <category_list>
          <category>
            <title>Total</title>
            <event_list>
              <event>
                <sub_title>Total, serious adverse events</sub_title>
                <counts group_id="E1" subjects_affected="0" subjects_at_risk="35"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="37"/>
              </event>
            </event_list>
          </category>
        </category_list>
      </serious_events>
      <other_events>
        <frequency_threshold>5</frequency_threshold>
        <category_list>
          <category>
            <title>Total</title>
            <event_list>
              <event>
                <sub_title>Total, other adverse events</sub_title>
                <counts group_id="E1" subjects_affected="0" subjects_at_risk="35"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="37"/>
              </event>
            </event_list>
          </category>
        </category_list>
      </other_events>
    </reported_events>

    <certain_agreements>
      <pi_employee>All Principal Investigators ARE employed by the organization sponsoring the study.</pi_employee>
      <restrictive_agreement>There is NOT an agreement between Principal Investigators and the Sponsor (or its agents) that restricts the PI's rights to discuss or publish trial results after the trial is completed. </restrictive_agreement>
    </certain_agreements>
    <point_of_contact>
      <name_or_title>Gunhilde Buchsbaum, Division Director Urogynecology</name_or_title>
      <organization>University of Rochester</organization>
      <phone>585-273-3233</phone>
      <email>gunhilde_buchsbaum@urmc.rochester.edu</email>
    </point_of_contact>
  </clinical_results>
</clinical_study>

